Johnson & Johnson scores 1st FDA label expansion for Imaavy

Just 16 months after Johnson & Johnson scored its initial FDA app | Sixteen months after Johnson & Johnson scored its initial FDA approval for Imaavy, the pharma giant has tacked on a label expansion for the monoclonal antibody. The U.S. regulator has signed off on Imaavy to treat warm autoimmune hemolytic anemia, a rare disorder which destroys red blood cells.